Search
INCB7839
go.drugbank.com/drugs/DB05033InvestigationalINCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. … It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.
Ularitide
go.drugbank.com/drugs/DB05034InvestigationalUlaritide is a synthetic form of urodilatin, a naturally occurring human natriuretic peptide that is involved in regulating blood pressure and the excretion of water and sodium from the kidneys. … Ularitide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF).
Eprotirome
go.drugbank.com/drugs/DB05035InvestigationalEprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia.
SGS518
go.drugbank.com/drugs/DB05042ExperimentalSGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).
Milveterol
go.drugbank.com/drugs/DB05043InvestigationalGSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
Cannabinor
go.drugbank.com/drugs/DB05048ExperimentalCannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
BZL101
go.drugbank.com/drugs/DB05051InvestigationalBZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
RG2417
go.drugbank.com/drugs/DB05055InvestigationalRG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential
GFT14
go.drugbank.com/drugs/DB05061ExperimentalGFT14 is a new class of medicaction for treatment of cardiometabolic disease. … GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides
Raseglurant
go.drugbank.com/drugs/DB05070InvestigationalADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).